The early onset of peripheral neuropathy might be a robust predictor for time to treatment failure in patients with metastatic breast cancer receiving chemotherapy containing paclitaxel.
Ippei FukadaYoshinori ItoKokoro KobayashiTomoko ShibayamaShunji TakahashiRie HoriiFutoshi AkiyamaTakuji IwaseShinji OhnoPublished in: PloS one (2017)
The early onset of peripheral neuropathy might be a robust predictor for TTF in patients with metastatic breast cancer treated with paclitaxel.